Fundraising FoxSpirair
South San Francisco, US · Delaware corporation · 3 known investors
Find your way into Spirair
Sign up to see every warm intro you have to Spirair
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Spirair team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Spirair develops minimally invasive, cartilage-preserving ENT (ear, nose, and throat) medical devices, including implants for correcting nasal septal deviation and supporting nasal passages after sinus surgery. Its products are aimed at ENT physicians treating conditions such as septal deviation and post-sinus-surgery turbinate issues.
Founders & leadership
Board
RB
Rob BinneyBoard director
CM
KG
Investors · 3
Reported raises · per SEC filings
Form D private placements$24.7M disclosed across 1 round · 2025
▶$24.7MraisedMar 2026 · 55 investors · Other Health CareRule 506(b)
▶$24.7MraisedMar 2026 · 55 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Rob BinneyDirector
- James KintzingExecutive Officer, Director
- Carter MeyerDirector
- Kate GarrettDirector
- Ben BishopExecutive Officer, Director
- Offering amount
- $28.2M
- Amount sold
- $24.7M
- Minimum investment
- $1
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Inspire MedicalInspire Medical Systems develops an FDA-approved implantable device that treats obstructive sleep apnea (OSA) by working with the patient's natural breathing, controlled via a small remote and intended for patients for whom CPAP is not effective. The device is surgically placed by an ENT and configured by a sleep medicine professional.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
PowerPower builds a patient-friendly platform to discover and enroll in clinical trials, serving patients seeking access to research studies and researchers seeking to improve patient recruitment. The company operates in the healthcare technology and clinical research industry.
Companies working in the same space as Spirair.
Frequently asked questions
- What does Spirair do?
- Spirair develops minimally invasive, cartilage-preserving ENT (ear, nose, and throat) medical devices, including implants for correcting nasal septal deviation and supporting nasal passages after sinus surgery. Its products are aimed at ENT physicians treating conditions such as septal deviation and post-sinus-surgery turbinate issues.
- Who are Spirair's investors?
- Spirair's investors include 1809 Capital, Sonder Capital, View Ventures.
- How much funding has Spirair raised?
- Spirair has disclosed $24.7M raised across 1 round.
- Where is Spirair headquartered?
- Spirair is headquartered in South San Francisco, US.